Does taking imatinib lower inflammation markers like TNF-alpha in chronic myeloid leukemia?
Imatinib, a first-line treatment for chronic myeloid leukemia (CML), works by blocking the BCR-ABL protein that drives cancer growth. It also appears to reduce inflammation. A 2024 study found that imatinib significantly lowers levels of tumor necrosis factor-alpha (TNF-alpha), a key inflammatory marker. High or persistent TNF-alpha levels were linked to worse treatment outcomes, suggesting that tracking this marker might help predict how well a patient responds to therapy.
What the research says
A prospective study of 40 CML patients treated with first-line imatinib measured serum TNF-alpha levels before and 5–7 months after starting treatment. Results showed that imatinib significantly reduced TNF-alpha from an average of 259.5 pg/mL to 129.8 pg/mL (p < 0.0001), mirroring the drop in BCR-ABL transcripts 6. The study also found that patients whose TNF-alpha levels remained high had poorer responses, while those with quicker clearance of TNF-alpha had better outcomes 6. This suggests that TNF-alpha could serve as a biomarker for treatment response in CML. The findings come from a single-center study in India, so larger and more diverse studies are needed to confirm these results. Other sources on imatinib focus on different aspects, such as genetic factors affecting drug levels 2 or gonadotoxicity 1, and do not directly address inflammation markers.
What to ask your doctor
- Should my TNF-alpha levels be monitored during imatinib treatment?
- Could persistent high TNF-alpha explain why my BCR-ABL levels are not dropping as expected?
- Are there other inflammation markers that might be relevant in my CML care?
- Would switching to a different TKI be considered if TNF-alpha remains elevated?
- How often should blood tests for inflammation be done while on imatinib?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.